XEFO, Lornoxicam, Tablets, lornoxicam 4mg, 8m, Medicine and Disease information

Members

Why a doctor should join epgonline.org ?

EPG Online Twitter

EPG Online Blog

Disease Knowledge

Drug Updates

EPG Search

XEFO overview

Short-term treatment of moderate postoperative pain, such as pain after dental surgery. Treatment of pain associated wih acute lumbo-sciatia. Symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis.

Social Networks

Drug Updates

banner_pass = 1

Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.

Change language Current language database: English

Related DrugsDrug Details

XEFO

Drug Class Description :

Non-steroidal anti-inflammatory drugs

Generic Name :

Lornoxicam

Drug description :

Film-coated tablets.

Presentation :

Tablets, lornoxicam 4mg, 8mg.

Indications :

Adult Dosage :

Postoperative pain/acute lumbo-sciatia, recommended daily dose, 8mg to 16mg taken before meals (daily doses above 8mg should be divided into two or more doses).

Maximum single dose, 8mg; maximum daily dose, 16mg. Osteoarthritis/Rheumatoid arthritis, recommended daily dose, 12 mg taken before meals (4mg three times daily or 8mg in the morning and 4mg at night); maximum recommended daily dose for long-term treatment, 12mg.

Child Dosage :

Under 18 years, not recommended

Elderly Dosage :

Monitoring of renal and heptic function is recommended.

Contra Indications :

Allergy to lornoxicam or any of the excipients. Previous hypersensitivity reactions (symptoms like asthma, rhintis, angioedema or urticaria) to other non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin (acetylsalicylic acid). Active peetic ulceration or a history of recurrent peptic ulceration. Severe renal impairment (serum creatinine > 700 micromol/ml). Pregnancy and lactation. Patients under 18 years of age.

Special Precautions :

In the following conditions Xefo should be administered only after careful risk-benefit asseseement. Gastrointestinal ulceration and bleeding in medical history; discontinue treatment if peptic ulceration and/or gastrointestinal bleeding occurs.

Renal impairment: mild (serum creatinine 150 to 300 micromol/l), monitor at one to two month intervals.

Blood coagulation disorders; careful monitoring recommended.

Liver disease (eg, cirrhosis); regular monitoring recommended. Long-term treatment (longer than three months), monitor haemoglobin, creatinine and liver enzymes regularly.

Elderly; monitor renal and hepatic function in patients over 65 years. Hypertension and/or obesity; monitor blood pressure and renal function. Monitor renal function in patients who are to undergo major surgery, with stressed renal function (eg, as a result of significant blood loss or severe dehydration), with cardiac failure, receiving concomitant treatment with diuretics or with drugs suspected or known to be able to cause kidney damage.

Interactions :

Anticoagulants or platelet aggregation inhibitors, sulphonylureas, other NSAIDs, diuretics, beta-blockers, ACE inhibitors, lithium, methotrexate, cimetidine, digoxin.

Adverse Reactions :

Most commonly (frqency 1 to 10%): abdominal pain, diarrhoea, dizziness, dyspepsia, headache, nausea, vomiting.

Rarely (frequency <1%): constipation, dysphagia, dry mouth, flatulence, gastritis, gastro-oesophageal reflux, peptic ulceration and/or gastrointestinal bleeding, stomatitis, haemorrhoidal bleeding, liver function abnormalities, alopecia, dermatitis, pruritus, increased sweating, micturition disorder, oedema, leg cramps paraesthesia, tremor, conjunctivitis, vision disorder, tinnitus, taste perversion, allergic reactions, anaemia, thrombocytopenia, increased bleeding time, ecchymoses, hypertension, palpitations, tachycardia, agitation, depression, insomnia, solnolence, alteration in appetite, weight changes, mylagia, malaise, weakness.

Manufacturer :

CeNeS

Drug Availability :

(POM)

Drug Updated :

17 June 2009

Related Drugs -

Opioid and Pain Management - understanding, management, diagnosis and treatment information

Ophthalmics - understanding, management, diagnosis and treatment information

Disease Knowledge – evidence based educational and clinical tools written for doctors and physicians

Disease Knowledge Centres feed

New and updated Drugs

UK Drugs
Fostair 100/6 inhalation solution Epanutin capsules 25, 50 and 100mg Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe FemSeven Conti Epanutin 300mg hard capsules Bedranol 80mg SR Capsules Bedranol 160mg SR Capsules Betim 10mg Tablets Carbo-Dome Cream Bisoprolol 2.5mg/5mg/10mg film coated tablet	Phenergan Injection Rivotril 0.5 mg and 2 mgTablets Rivotril Ampoules RELPAX 20mg and 40mg Film-Coated Tablets Witch Doctor ® 81.5%w/w Gel Levetiracetam Actavis 1,000 mg film-coated tablets Levetiracetam Actavis 250 mg film-coated tablets Levetiracetam Actavis 500 mg film-coated tablets Levetiracetam Actavis 750 mg film-coated tablets Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules

Spanish Drugs
Benlysta 400 mg polvo para concentrado para solución para perfusión. Benlysta 120 mg polvo para concentrado para solución para perfusión. Qutenza 179 mg parche cutáneo MULTAQ 400 mg comprimidos recubiertos con película Onglyza 2,5 mg comprimidos recubiertos con película IRESSA 250 mg comprimidos recubiertos con película Mycamine 50 mg polvo para solución para perfusión Protopic 0,03% pomada Protopic 0,1% pomada Cayston 75 mg polvo y disolvente para solución para inhalación por nebulizador	Altargo 1% pomada Xarelto 15 mg comprimidos recubiertos con película Xarelto 10 mg comprimidos recubiertos con película Xarelto 20 mg comprimidos recubiertos con película BRINAVESS 20 mg/ml, concentrado para solución para perfusión MEPACT 4 mg polvo para suspensión para perfusión. Fablyn Nebido 1000mg/4ml Testogel Nebido

German Drugs
Benlysta 120 mg Pulver zur Herstellung eines Infusionslösungskonzentrats. Benlysta 400 mg Pulver zur Herstellung eines Infusionslösungskonzentrats. MULTAQ® 400 mg Filmtabletten Qutenza 179 mg kutanes Pflaster Onglyza 2,5 mg Filmtabletten Protopic 0,1% Salbe IRESSA 250 mg Filmtabletten Mycamine 50 mg Pulver zur Herstellung einer Infusionslösung Vistide 75 mg/ml Konzentrat zur Herstellung einer Infusionslösung Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler	Protopic 0,03% Salbe Xarelto 20 mg Filmtabletten Xarelto 15 mg Filmtabletten Xarelto 10 mg Filmtabletten Mycophenolatmofetil Teva 250 mg Hartkapseln Humira 40 mg MEPACT 4 mg Pulver zur Herstellung einer Infusionssuspension FABLYN Testogel Nebido 1000mg/4ml

Norweigan Drugs
Benlysta 120 mg pulver til konsentrat til infusjonsvæske, oppløsning. Benlysta 400 mg pulver til konsentrat til infusjonsvæske, oppløsning. Qutenza 179 mg hudplaster Onglyza 2,5 mg filmdrasjerte tabletter. IRESSA 250 mg, filmdrasjerte tabletter Protopic 0,1 % salve Mycamine 50 mg pulver til infusjonsvæske, oppløsning Cayston 75 mg pulver og væske til inhalasjonsvæske til nebulisator, oppløsning Xarelto 20 mg tabletter, filmdrasjerte Xarelto 15 mg tabletter, filmdrasjerte	Xarelto 10 mg tabletter, filmdrasjerte Fungizone Kabikinase Insulin Insulatard Flunitec Insulin Monotard Insulin Mixtard 50/50 Insulin Mixtard 40/60 Hivid Insulin Mixtard 20/80

Netherlands Drugs
Benlysta 120 mg poeder voor concentraat voor oplossing voor infusie. Benlysta 400 mg poeder voor concentraat voor oplossing voor infusie. Qutenza 179 mg huidpleister Onglyza 2,5 mg, filmomhulde tabletten IRESSA 250 mg filmomhulde tabletten Mycamine 50 mg poeder voor oplossing voor infusie Protopic 0,1% zalf Cayston 75 mg poeder en oplosmiddel voor verneveloplossing Protopic 0,03% zalf Xarelto 20 mg filmomhulde tabletten	Xarelto 15 mg filmomhulde tabletten Xarelto 10 mg filmomhulde tabletten Polyspectran Tobrex Tetracycline Oogdruppels FNA Zarontin Gentamytrex Ethymal Irgamid Polytrim
Swedish Drugs
Benlysta 400 mg pulver till koncentrat till infusionsvätska, lösning. Benlysta 120 mg pulver till koncentrat till infusionsvätska, lösning. Qutenza 179 mg kutant plåster Onglyza 2,5 mg filmdragerade tabletter IRESSA 250 mg filmdragerade tabletter Mycamine 50 mg pulver till infusionsvätska, lösning Protopic 0,1% salva Cayston 75 mg pulver och vätska till lösning för nebulisator Xarelto 15 mg filmdragerade tabletter Xarelto 20 mg filmdragerade tabletter	Xarelto 10 mg filmdragerade tabletter Ketek 400 mg filmdragerade tabletter Tasigna 200 mg hårda kapslar Advate Injektionsvätska, lösning Axura 10 mg/g orala droppar, lösning Axura 10 mg filmdragerade tabletter Myozyme 50 mg, pulver till koncentrat till infusionsvätska, lösning Onbrez Breezhaler 300 mikrogram inhalationspulver, hårda kapslar Hepsera 10 mg tabletter Champix filmdragerade tabletter

French Drugs
Benlysta 120 mg poudre pour solution à diluer pour perfusion. Benlysta 400 mg poudre pour solution à diluer pour perfusion Qutenza 179 mg patch cutané. Onglyza 2,5 mg, comprimés pelliculés IRESSA 250 mg, comprimés pelliculés Mycamine 50 mg poudre pour solution pour perfusion Protopic 0,1% pommade VISTIDE 75 mg/ml, solution à diluer pour perfusion CANCIDAS 50 mg poudre pour solution à diluer pour perfusion Cubicin 350 mg poudre pour solution à diluer pour perfusion	ECALTA 100 mg poudre et solvant pour solution à diluer pour perfusion Altargo 1% pomada Protopic 0,03% pommade Xarelto 20 mg comprimé pelliculé Xarelto 15 mg comprimé pelliculé Xarelto 10 mg comprimé pelliculé Herceptin 150 mg poudre pour solution à diluer pour perfusion ACETYLCYSTEINE BIOGARAN CONSEIL 200 mg, poudre pour solution buvable en sachet ACETYLLEUCINE BIOGARAN 500 mg, comprimé ACETYLLEUCINE ZENTIVA 500 mg, comprimé

Portuguese Drugs
Benlysta 400 mg pó para concentrado para solução para perfusão Benlysta 120 mg pó para concentrado para solução para perfusão. Qutenza 179 mg adesivo cutâneo Onglyza 2,5 mg comprimidos revestidos por película IRESSA 250 mg comprimidos revestidos por película Protopic 0,1% pomada Mycamine 50 mg pó para solução para perfusão Vistide 75 mg/ml concentrado para solução para perfusão ECALTA 100 mg pó e solvente para concentrado para solução para perfusão CANCIDAS 50 mg pó para concentrado para solução para perfusão	Cubicin 350 mg pó para solução injetável ou para perfusão Protopic 0,03% pomada Xarelto 20 mg comprimidos revestidos por película Xarelto 15 mg comprimidos revestidos por película Xarelto 10 mg comprimidos revestidos por película Tredaptive Truvada Trevaclyn Trisenox Trizivir

Italian Drugs
Benlysta 400 mg polvere per concentrato per soluzione per infusione. Benlysta 120 mg polvere per concentrato per soluzione per infusione Qutenza 179 mg cerotto cutaneo Onglyza 2,5 mg compresse rivestite con film Mycamine 50 mg polvere per soluzione per infusione Vistide 75 mg/ml concentrato per soluzione per infusione CANCIDAS 50 mg polvere per concentrato per soluzione per infusione ECALTA 100 mg polvere e solvente per concentrato per soluzione per infusione Cubicin 350 mg polvere per soluzione iniettabile o per infusione Altargo 1% unguento	Protopic 0,03% unguento Xarelto 20 mg compresse rivestite con film Xarelto 15 mg compresse rivestite con film Xarelto 10 mg compresse rivestite con film MEPACT 4 mg polvere per sospensione per infusione FABLYN Testogel Nebido Levitra Xelevia 25 mg compresse rivestite con film

Atopic Dermatitis

CONNECT

DISEASE CENTRES

AFFILIATE PARTNERS

QUICK SEARCH

GUIDELINES

DRUG DATA

REFERENCES